Beigene Ltd share price today

(BGNE)

Beigene Ltd share price is $205.62 & ₹17,413.96 as on 7 Dec 2024, 2.30 'hrs' IST

$205.62

▲

3.96

(1.96%)

Market is closed - opens 8 PM, 09 Dec 2024

View live Beigene Ltd share price in Dollar and Rupees. Guide to invest in Beigene Ltd from India. Also see the sentimental analysis on Indian investors investing in Beigene Ltd. Get details on the Indian mutual funds that are investing in Beigene Ltd. Get Analyst recommendations and forecasts along with all the Beigene Ltd's financials.

Beigene Ltd share price movements

$204.28
$209.25
$205.62
0.65%
Downside
Day's Volatility :2.38%
Upside
1.73%
$126.97
$248.16
$205.62
38.25%
Downside
52 Weeks Volatility :48.84%
Upside
17.14%

Beigene Ltd Returns

Period	Beigene Ltd	Sector (Health Care)	Index (Russel 2000)
3 Months	4.32%	-5.7%	0.0%
6 Months	29.21%	-0.9%	0.0%
1 Year	15.54%	9.9%	0.0%
3 Years	-32.43%	8.4%	-22.1%

Beigene Ltd Key Statistics

in dollars & INR

Previous Close	$201.66
Open	$207.72
Today's High	$209.25
Today's Low	$204.28
Market Capitalization	$22.8B
Today's Volume	$261.1K
52 Week High	$248.16
52 Week Low	$126.9681
Revenue TTM	$23.5B
EBITDA	$-5.6B
Earnings Per Share (EPS)	$-7.92
Profit Margin	-25.5%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-23.22%

How to invest in Beigene Ltd from India?

It is very easy for Indian residents to invest directly in Beigene Ltd from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Beigene Ltd stock in both rupees (INR) and dollars (USD). Search for Beigene Ltd or BGNE on INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Beigene Ltd or Rupee/ Dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Beigene Ltd shares which would translate to 0.004 fractional shares of Beigene Ltd as of today. Learn more about fractional investing here.

Indians via INDmoney can now also, easily transfer and add their money to the US stocks account via INDmoney App. Click here for step by step process for the same

Indian investors sentiment towards Beigene Ltd

-34.29%

Period: Sep 9, 2024 to Dec 8, 2024. Change in 30 Days versus previous period

Investment in Beigene Ltd from India has reduced in the last 30 days as on Dec 9, 2024. -34.29% less purchase transactions for Beigene Ltd in the last 30 days versus the previous period.

-69%

Period: Sep 9, 2024 to Dec 8, 2024. Change in 30 Days versus previous period

Search volume for Beigene Ltd on INDmoney from India has reduced in the last 30 days as on Dec 9, 2024. -69% less investors are searching Beigene Ltd in the last 30 days versus the previous period.

Global Institutional Holdings in Beigene Ltd

Baker Bros Advisors LP
9.94%
Capital Research & Mgmt Co - Division 3
6.05%
Hillhouse Capital Advisors, Ltd.
4.87%
PRIMECAP Management Company
4.68%
Baillie Gifford & Co Limited.
3.49%
T. Rowe Price Associates, Inc.
2.54%

Analyst Recommendation on Beigene Ltd

Buy

92%Buy

7%Hold

0%Sell

Based on 13 Wall street analysts offering stock ratings for Beigene Ltd(by analysts ranked 0 to 5 stars)

Based on 13 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Beigene Ltd

What analysts predicted

Upside of 36.05%

Current:

$205.62

Target:

$279.75

Insights on Beigene Ltd

Increasing Revenue
Revenue is up for the last 4 quarters, 634.40M → 1.00B (in $), with an average increase of 14.0% per quarter
Decreasing Net Profit
Netprofit is down for the last 2 quarters, -120.40M → -121.35M (in $), with an average decrease of 0.8% per quarter
Vs ALNY
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 48.1% return, outperforming this stock by 32.9%
Vs VRTX
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 42.3% return, outperforming this stock by 78.3%

Beigene Ltd Financials in INR & Dollars

	FY18	Y/Y Change
Revenue	$198.2M	↓ 16.85%
Net Income	$-673.8M	↑ 623.67%
Net Profit Margin	-339.91%	↓ 300.85%

	FY19	Y/Y Change
Revenue	$428.2M	↑ 116.03%
Net Income	$-950.6M	↑ 41.08%
Net Profit Margin	-221.99%	↑ 117.92%

	FY20	Y/Y Change
Revenue	$308.9M	↓ 27.87%
Net Income	$-1.6B	↑ 68.37%
Net Profit Margin	-518.18%	↓ 296.19%

	FY21	Y/Y Change
Revenue	$1.2B	↑ 280.83%
Net Income	$-1.4B	↓ 11.69%
Net Profit Margin	-120.15%	↑ 398.03%

	FY22	Y/Y Change
Revenue	$1.4B	↑ 20.37%
Net Income	$-2.0B	↑ 41.78%
Net Profit Margin	-141.52%	↓ 21.37%

	FY23	Y/Y Change
Revenue	$2.5B	↑ 73.65%
Net Income	$-881.7M	↓ 56.0%
Net Profit Margin	-35.86%	↑ 105.66%

	Q2 FY23	Q/Q Change
Revenue	$595.3M	↑ 32.93%
Net Income	$-381.1M	↑ 9.39%
Net Profit Margin	-64.03%	↑ 13.78%

	Q3 FY23	Q/Q Change
Revenue	$781.3M	↑ 31.25%
Net Income	$215.4M	↓ 156.52%
Net Profit Margin	27.57%	↑ 91.6%

	Q4 FY23	Q/Q Change
Revenue	$634.4M	↓ 18.8%
Net Income	$-367.6M	↓ 270.63%
Net Profit Margin	-57.94%	↓ 85.51%

	Q1 FY24	Q/Q Change
Revenue	$751.7M	↑ 18.48%
Net Income	$-251.2M	↓ 31.67%
Net Profit Margin	-33.41%	↑ 24.53%

	Q2 FY24	Q/Q Change
Revenue	$929.2M	↑ 23.62%
Net Income	$-120.4M	↓ 52.06%
Net Profit Margin	-12.96%	↑ 20.45%

	Q3 FY24	Q/Q Change
Revenue	$1.0B	↑ 7.8%
Net Income	$-121.4M	↑ 0.78%
Net Profit Margin	-12.12%	↑ 0.84%

	FY18	Y/Y Change
Total Assets	$2.2B	↑ 114.98%
Total Liabilities	$496.0M	↑ 36.93%

	FY19	Y/Y Change
Total Assets	$1.6B	↓ 28.33%
Total Liabilities	$633.9M	↑ 27.8%

	FY20	Y/Y Change
Total Assets	$5.6B	↑ 247.38%
Total Liabilities	$1.7B	↑ 173.14%

	FY21	Y/Y Change
Total Assets	$8.6B	↑ 54.37%
Total Liabilities	$2.4B	↑ 38.78%

	FY22	Y/Y Change
Total Assets	$6.4B	↓ 26.22%
Total Liabilities	$2.0B	↓ 16.94%

	FY23	Y/Y Change
Total Assets	$5.8B	↓ 9.0%
Total Liabilities	$2.3B	↑ 13.63%

	Q2 FY23	Q/Q Change
Total Assets	$5.7B	↓ 3.83%
Total Liabilities	$1.9B	↑ 7.26%

	Q3 FY23	Q/Q Change
Total Assets	$5.5B	↓ 3.56%
Total Liabilities	$1.8B	↓ 8.73%

	Q4 FY23	Q/Q Change
Total Assets	$5.8B	↑ 5.08%
Total Liabilities	$2.2B	↑ 26.8%

	Q1 FY24	Q/Q Change
Total Assets	$5.7B	↓ 2.37%
Total Liabilities	$2.3B	↑ 1.82%

	Q2 FY24	Q/Q Change
Total Assets	$5.7B	↑ 0.79%
Total Liabilities	$2.3B	↑ 3.15%

	Q3 FY24	Q/Q Change
Total Assets	$5.8B	↑ 2.08%
Total Liabilities	$2.4B	↑ 2.08%

	FY18	Y/Y Change
Operating Cash Flow	$-547.7M	↓ 4395.15%
Investing Cash Flow	$-637.6M	↑ 78.94%
Financing Cash Flow	$1.7B	↑ 244.76%

	FY19	Y/Y Change
Operating Cash Flow	$-750.3M	↑ 36.98%
Investing Cash Flow	$554.2M	↓ 186.91%
Financing Cash Flow	$85.7M	↓ 94.93%

	FY20	Y/Y Change
Operating Cash Flow	$-1.3B	↑ 71.07%
Investing Cash Flow	$-3.2B	↓ 671.74%
Financing Cash Flow	$5.2B	↑ 5972.39%

	FY21	Y/Y Change
Operating Cash Flow	$-1.3B	↑ 1.19%
Investing Cash Flow	$640.7M	↓ 120.22%
Financing Cash Flow	$3.6B	↓ 30.1%

	FY22	Y/Y Change
Operating Cash Flow	$-1.5B	↑ 15.24%
Investing Cash Flow	$1.1B	↑ 68.13%
Financing Cash Flow	$-19.0M	↓ 100.52%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$-293.9M	↓ 47.87%
Investing Cash Flow	$67.8M	↑ 0.0%
Financing Cash Flow	$166.1M	↓ 935.92%

	Q3 FY23	Q/Q Change
Operating Cash Flow	$-78.2M	↓ 73.41%
Investing Cash Flow	$-186.3M	↓ 374.74%
Financing Cash Flow	$-76.8M	↓ 146.23%

Beigene Ltd Technicals Summary

Sell

Neutral

Buy

Beigene Ltd is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Beigene Ltd Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Beigene Ltd	-1.85%	29.21%	15.54%	-32.43%	12.08%
Beigene Ltd	-7.31%	-23.34%	-9.49%	14.69%	105.58%
Beigene Ltd	7.41%	21.29%	18.26%	-53.88%	279.68%
Beigene Ltd	-9.23%	64.08%	47.33%	45.01%	111.98%
Beigene Ltd	-11.0%	-4.83%	29.09%	121.05%	109.05%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Beigene Ltd	NA	NA	0.0	-5.65	-0.23	-0.1	NA	226.72
Beigene Ltd	18.56	18.56	1.12	44.92	0.17	0.07	NA	272.04
Beigene Ltd	160.8	NA	0.04	-3.06	-0.02	-0.01	NA	79.73
Beigene Ltd	NA	NA	-0.49	-0.19	-15.01	-0.03	NA	0.25
Beigene Ltd	32.84	NA	1.21	0.54	-0.03	0.12	NA	60.65

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Beigene Ltd	Buy	$22.8B	12.08%	NA	-25.5%
Beigene Ltd	Buy	$82.9B	105.58%	18.56	33.61%
Beigene Ltd	Buy	$28.5B	279.68%	160.8	-15.36%
Beigene Ltd	Buy	$32.7B	111.98%	NA	-15.86%
Beigene Ltd	Buy	$118.4B	109.05%	32.84	-4.51%

Beigene Ltd Dividend announcements

Beigene Ltd Earnings
Beigene Ltd’s price-to-earnings ratio stands at None
Read More

About Beigene Ltd

BeiGene is a biotechnology company that specializes in the development of drugs for cancer treatment. BeiGene has developed several pharmaceuticals, including tislelizumab, a checkpoint inhibitor, and zanubrutinib.

Organization	Beigene Ltd
Employees	10600
CEO	Mr. John V. Oyler
Industry	Health Technology

Management People of Beigene Ltd

Name	Title
Mr. John V. Oyler	Co-Founder, Executive Chairman & CEO
Dr. Xiaobin Wu Ph.D.	President & COO
Dr. Xiaodong Wang Ph.D.	Co-Chairman of Scientific Advisory Board & Non-Executive Director and Co-Founder
Mr. Chan Lee	General Counsel & Senior VP
Mr. Wang Lai Ph.D.	Global Head of R&D
Mr. Aaron Rosenberg	CFO & Principal Financial Officer
Mr. Titus B. Ball	VP & Chief Accounting Officer
Ms. Liza Heapes	Head of Investor Relations
Mr. Yang Ji	Chief Compliance Officer
Dr. Yan Qi	Senior VP & Head of Public Affairs - Greater China

Important FAQs about investing in Beigene Ltd from India :

What is Beigene Ltd share price today?

Beigene Ltd (BGNE) share price today is $205.62.

Can Indians buy Beigene Ltd shares?

Yes, Indians can invest in the Beigene Ltd (BGNE) from India.

With INDmoney, you can buy Beigene Ltd at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Beigene Ltd at zero transaction cost.

How can I buy Beigene Ltd shares from India?

It is very easy to buy Beigene Ltd from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Beigene Ltd be purchased?

Yes, you can buy fractional shares of Beigene Ltd with INDmoney app.

What are the documents required to start investing in Beigene Ltd stocks?

To start investing in Beigene Ltd, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.